Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment

Journal of Controlled Release

Volumn 159, Issue 2, 2012, Pages 281-289

  Van Der Meel, Roy ^a   Oliveira, Sabrina ^b,c   Altintas, Isil ^a   Haselberg, Rob ^b   Van Der Veeken, Joris ^a   Roovers, Rob C ^b   Van Bergen En Henegouwen, Paul M P ^b   Storm, Gert ^a   Hennink, Wim E ^a   Schiffelers, Raymond M ^a,c   Kok, Robbert J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Combination therapy; EGFR; IGF 1R; Immunoliposomes; Nanobody

Indexed keywords

COMBINATION THERAPY; EGFR; IGF-1R; IMMUNOLIPOSOMES; NANOBODY;

CELL PROLIFERATION; DISEASES; ENZYME INHIBITION;

LIPOSOMES;

AG 538; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LIPOSOME; NANOMATERIAL; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BLOTTING, WESTERN; CATECHOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG COMPOUNDING; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LIPOSOMES; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NIH 3T3 CELLS; PARTICLE SIZE; PROTEIN KINASE INHIBITORS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SURFACE PROPERTIES; TYRPHOSTINS;

EID: 84861101022     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.12.027     Document Type: Article

References (22)

1. S. Oliveira, P.M. van Bergen en Henegouwen, G. Storm, and R.M. Schiffelers Molecular biology of epidermal growth factor receptor inhibition for cancer therapy Expert. Opin. Biol. Ther. 6 2006 605 617 (Pubitemid 43837187)
2. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N. Engl. J. Med. 358 2008 1160 1174
3. A. Harandi, A.S. Zaidi, A.M. Stocker, and D.A. Laber Clinical efficacy and toxicity of anti-EGFR therapy in common cancers J. Oncol. 2009 2009 567486
4. D.L. Wheeler, E.F. Dunn, and P.M. Harari Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat. Rev. Clin. Oncol. 7 2010 493 507
5. J. van der Veeken, S. Oliveira, R.M. Schiffelers, G. Storm, P.M. van Bergen en Henegouwen, and R.C. Roovers Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy Curr. Cancer Drug Targets 9 2009 748 760
6. M. Pollak Insulin and insulin-like growth factor signalling in neoplasia Nat. Rev. Cancer 8 2008 915 928
7. A. Gualberto, and M. Pollak Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions Oncogene 28 2009 3009 3021
8. S. Oliveira, R.M. Schiffelers, J. van der Veeken, R. van der Meel, R. Vongpromek, P.M. van Bergen en Henegouwen, G. Storm, and R.C. Roovers Downregulation of EGFR by a novel multivalent nanobody-liposome platform J. Control. Release 145 2010 165 175
9. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman, and R. Hamers Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448 (Pubitemid 23179389)
10. G. Blum, A. Gazit, and A. Levitzki Substrate competitive inhibitors of IGF-1 receptor kinase Biochemistry 39 2000 15705 15712 (Pubitemid 32038232)
11. E.G. Hofman, M.O. Ruonala, A.N. Bader, D. van den Heuvel, J. Voortman, R.C. Roovers, A.J. Verkleij, H.C. Gerritsen, and P.M. van Bergen en Henegouwen EGF induces coalescence of different lipid rafts J. Cell Sci. 121 2008 2519 2528
12. S. Spinelli, L.G. Frenken, P. Hermans, T. Verrips, K. Brown, M. Tegoni, and C. Cambillau Camelid heavy-chain variable domains provide efficient combining sites to haptens Biochemistry 39 2000 1217 1222 (Pubitemid 30090687)
13. R.C. Roovers, P. Henderikx, W. Helfrich, E. van der Linden, A. Reurs, A.P. de Bruine, J.W. Arends, L. de Leij, and H.R. Hoogenboom High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting Br. J. Cancer 78 1998 1407 1416 (Pubitemid 28517535)
14. D. Zucker, D. Marcus, Y. Barenholz, and A. Goldblum Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties J. Control. Release 139 2009 73 80
15. R. Haselberg, S. Harmsen, M.E. Dolman, G.J. de Jong, R.J. Kok, and G.W. Somsen Characterization of drug-lysozyme conjugates by sheathless capillary electrophoresis-time-of-flight mass spectrometry Anal. Chim. Acta 698 2011 77 83
16. R. Haselberg, C.K. Ratnayake, G.J. de Jong, and G.W. Somsen Performance of a sheathless porous tip sprayer for capillary electrophoresis-electrospray ionization-mass spectrometry of intact proteins J. Chromatogr. A 1217 2010 7605 7611
17. G. Rouser, S. Fkeischer, and A. Yamamoto Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots Lipids 5 1970 494 496
18. A.M. Honegger, T.J. Dull, S. Felder, E. Van Obberghen, F. Bellot, D. Szapary, A. Schmidt, A. Ullrich, and J. Schlessinger Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing Cell 51 1987 199 209
19. L.M. Friedman, A. Rinon, B. Schechter, L. Lyass, S. Lavi, S.S. Bacus, M. Sela, and Y. Yarden Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy Proc. Natl. Acad. Sci. U. S. A. 102 2005 1915 1920 (Pubitemid 40261987)
20. P.H. Shaw, T.S. Maughan, and A.R. Clarke Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse Br. J. Cancer 2011
21. C.E. Galer, C.L. Corey, Z. Wang, M.N. Younes, F. Gomez-Rivera, S.A. Jasser, D.L. Ludwig, A.K. El-Naggar, R.S. Weber, and J.N. Myers Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma Head Neck 33 2011 189 198
22. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151